A study at Stanford University School of Medicine say that a greater percentage of patients than previously thought may develop heart failure when taking the breakthrough cancer drug Sutent.
The study author reports that data support a role for routine cardiac monitoring for patients receiving sunitinib [Sutent] and careful study of adverse cardiac events in future studies. Sunitinib is being investigated in over 30 different tumor types for advanced as well as early forms of cancer. This investigation will help to determine what factors put patients at increased risk and will allow doctors to administer this medication more safely for patients whose benefits clearly outweigh the risks.
The drug was approved for advanced kidney cancer and a rare form of gastrointestinal cancer.
No User Responded In This Post
Leave Your Comments Here...